Böttcher Sebastian, Ritgen Matthias, Kneba Michael
Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.
Methods Mol Biol. 2013;971:149-74. doi: 10.1007/978-1-62703-269-8_9.
The quantification of submicroscopic minimal residual disease (MRD) after therapy proved to have independent prognostic significance in many mature B-cell malignancies. With the advent of routine bench-top cytometers capable of simultaneously analyzing ≥ 4 colors and with improved standardization, flow cytometry has become the method of choice for MRD assessments in some lymphoma entities. Herein we describe general aspects of flow cytometric standardization. Using chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) as examples we explain in detail the application of flow cytometry for MRD detection.
治疗后亚微观微小残留病（MRD）的定量在许多成熟B细胞恶性肿瘤中被证明具有独立的预后意义。随着能够同时分析≥4种颜色的常规台式细胞仪的出现以及标准化的改进，流式细胞术已成为某些淋巴瘤实体中MRD评估的首选方法。在此我们描述流式细胞术标准化的一般方面。以慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤（MCL）为例，我们详细解释流式细胞术在MRD检测中的应用。
